B淋巴细胞刺激因子/增殖诱导配体（BLyS/BAFF）配体与受体家族：自身免疫治疗及理解中的关键靶点
The BLyS/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity.
作者信息
Cancro M P
机构信息
Department of Pathology, 284 John Morgan Building, University of Pennsylvania School of Medicine, 36th and Hamilton Walk, Philadelphia, PA 19104-6082, USA.
出版信息
Ann Rheum Dis. 2006 Nov;65 Suppl 3(Suppl 3):iii34-6. doi: 10.1136/ard.2006.058412.
Abstract
The B lymphocyte stimulator (BLyS; also termed BAFF) family of ligands and receptors plays a central role in B lymphocyte development, selection, and homoeostasis. Members of this family can independently influence different B cell subsets, because the interactions between the two ligands and three receptors vary, and the receptors themselves are differentially expressed among developing, naive, and antigen experienced B cell subsets. These properties prompt careful assessment of how ablative therapies may influence the behaviour of upstream or downstream B lineage populations, as well as how the implementation and expectations of therapeutics targeting BLyS family members must be guided by knowledge of the B cell subsets contributing to pathogenesis.
摘要
B淋巴细胞刺激因子（BLyS；也称为BAFF）配体和受体家族在B淋巴细胞的发育、选择和稳态中起着核心作用。该家族成员可独立影响不同的B细胞亚群，因为两种配体与三种受体之间的相互作用各不相同，且这些受体在发育中的、未活化的以及经历过抗原刺激的B细胞亚群中表达各异。这些特性促使我们仔细评估消融疗法如何影响上游或下游B细胞谱系群体的行为，以及针对BLyS家族成员的治疗方法的实施和预期如何必须以对参与发病机制的B细胞亚群的了解为指导。
相似文献
1
The BLyS/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity.
Ann Rheum Dis. 2006 Nov;65 Suppl 3(Suppl 3):iii34-6. doi: 10.1136/ard.2006.058412.
2
Manipulating B cell homeostasis: a key component in the advancement of targeted strategies.
Arch Immunol Ther Exp (Warsz). 2008 May-Jun;56(3):153-64. doi: 10.1007/s00005-008-0017-2. Epub 2008 May 30.
3
The BLyS family: toward a molecular understanding of B cell homeostasis.
Cell Biochem Biophys. 2009;53(1):1-16. doi: 10.1007/s12013-008-9036-1. Epub 2008 Nov 26.
4
B-cell homeostasis requires complementary CD22 and BLyS/BR3 survival signals.
Int Immunol. 2010 Aug;22(8):681-91. doi: 10.1093/intimm/dxq055. Epub 2010 May 31.
5
The late news on baff in autoimmune diseases.
Autoimmun Rev. 2010 Oct;9(12):804-6. doi: 10.1016/j.autrev.2010.06.011. Epub 2010 Jul 23.
6
BAFF inhibition: a new class of drugs for the treatment of autoimmunity.
Exp Cell Res. 2011 May 15;317(9):1270-7. doi: 10.1016/j.yexcr.2011.02.005. Epub 2011 Feb 17.
7
The role of B lymphocyte stimulator in B cell biology: implications for the treatment of lupus.
Lupus. 2013 Apr;22(4):350-60. doi: 10.1177/0961203312469453.
8
Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease.
Immunopharmacol Immunotoxicol. 2021 Dec;43(6):666-673. doi: 10.1080/08923973.2021.1973493. Epub 2021 Sep 14.
9
Mechanism of BLyS action in B cell immunity.
Cytokine Growth Factor Rev. 2002 Feb;13(1):19-25. doi: 10.1016/s1359-6101(01)00025-9.
10
The role of BAFF and APRIL in rheumatoid arthritis.
J Cell Physiol. 2019 Aug;234(10):17050-17063. doi: 10.1002/jcp.28445. Epub 2019 Apr 2.
引用本文的文献
1
Therapeutic Potential of Lipid Nanoparticle-Encapsulated CD19-Targeting mRNAs in Lupus and Rheumatoid Arthritis.
Adv Sci (Weinh). 2025 Jun;12(21):e2501628. doi: 10.1002/advs.202501628. Epub 2025 Apr 7.
2
Evolving Treatment Strategies for Systemic Lupus Erythematosus in Clinical Practice: A Narrative Review.
Cureus. 2024 Dec 3;16(12):e75062. doi: 10.7759/cureus.75062. eCollection 2024 Dec.
3
Immunotherapy for Pemphigus: Present and Future.
Front Med (Lausanne). 2022 Jun 15;9:901239. doi: 10.3389/fmed.2022.901239. eCollection 2022.
4
Altered Germinal-Center Metabolism in B Cells in Autoimmunity.
Metabolites. 2022 Jan 5;12(1):40. doi: 10.3390/metabo12010040.
5
Identifying Safety Thresholds for Immunosuppressive Drugs: Applying Insights from Primary Antibody Deficiencies to Mitigate Adverse Events in Secondary Antibody Deficiencies Using Mathematical Modeling of Preclinical and Early Clinical Data.
Eur J Drug Metab Pharmacokinet. 2021 Sep;46(5):601-611. doi: 10.1007/s13318-021-00706-z. Epub 2021 Jul 30.
6
Innate Immunity and Biological Therapies for the Treatment of Sjögren's Syndrome.
Int J Mol Sci. 2020 Dec 1;21(23):9172. doi: 10.3390/ijms21239172.
7
Phage Display Derived Monoclonal Antibodies: From Bench to Bedside.
Front Immunol. 2020 Aug 28;11:1986. doi: 10.3389/fimmu.2020.01986. eCollection 2020.
8
Regulatory and Memory B Lymphocytes in Children With Newly Diagnosed Immune Thrombocytopenia.
J Hematol. 2017 Oct;6(4):81-86. doi: 10.14740/jh336w. Epub 2017 Sep 20.
9
B cell phenotypes in patients with rheumatoid arthritis relapsing after rituximab: expression of B cell-activating factor-binding receptors on B cell subsets.
Clin Exp Immunol. 2017 Dec;190(3):372-383. doi: 10.1111/cei.13024. Epub 2017 Sep 25.
10
Effect of rituximab on B cell phenotype and serum B cell-activating factor levels in patients with thrombotic thrombocytopenic purpura.
Clin Exp Immunol. 2015 Mar;179(3):414-25. doi: 10.1111/cei.12472.
本文引用的文献
1
Space, selection, and surveillance: setting boundaries with BLyS.
J Immunol. 2006 Jun 1;176(11):6405-10. doi: 10.4049/jimmunol.176.11.6405.
2
The role of APRIL and BAFF in lymphocyte activation.
Curr Opin Immunol. 2005 Jun;17(3):282-9. doi: 10.1016/j.coi.2005.04.005.
3
Homeostatic niche specification among naïve and activated B cells: a growing role for the BLyS family of receptors and ligands.
Semin Immunol. 2005 Jun;17(3):193-9. doi: 10.1016/j.smim.2005.02.001.
4
The role of BAFF in immune function and implications for autoimmunity.
Immunol Rev. 2005 Apr;204:43-54. doi: 10.1111/j.0105-2896.2005.00219.x.
5
Human B lymphocyte malignancies: exploitation of BLyS and APRIL and their receptors.
Curr Dir Autoimmun. 2005;8:266-88. doi: 10.1159/000082107.
6
The BAFF/APRIL system: an important player in systemic rheumatic diseases.
Curr Dir Autoimmun. 2005;8:243-65. doi: 10.1159/000082106.
7
The BLyS family of ligands and receptors: an archetype for niche-specific homeostatic regulation.
Immunol Rev. 2004 Dec;202:237-49. doi: 10.1111/j.0105-2896.2004.00212.x.
8
Structures of APRIL-receptor complexes: like BCMA, TACI employs only a single cysteine-rich domain for high affinity ligand binding.
J Biol Chem. 2005 Feb 25;280(8):7218-27. doi: 10.1074/jbc.M411714200. Epub 2004 Nov 12.
9
A therapeutic role for BLyS antagonists.
Lupus. 2004;13(5):317-22. doi: 10.1191/0961203304lu1019oa.
10
Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches.
Immunity. 2004 Jun;20(6):785-98. doi: 10.1016/j.immuni.2004.05.010.
Zotero 插件